Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIADA: Nivolumab + Chemo-endocrine Therapy in Luminal B Breast Cancer
NCT04659551Phase 2Completed
- Sponsor
- Istituto Oncologico Veneto
- Start
- Oct 2017
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in breast cancer, sponsored by Istituto Oncologico Veneto. Primary endpoint: Pathological Complete Response at 7 months. Started Oct 2017; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04659551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04659551.